Matthew N Meriggioli - JoVE Visualize

Showing results (31-40 of 33) with videos related to

Pageof 4

Sort By:

You have reached the last page of results.This site can display upto 33 results.

Human Mutation|September 18, 2010

Novel LMNA mutations in patients with Emery-Dreifuss muscular dystrophy and functional characterization of four LMNA mutationsJuergen Scharner, Charlotte A Brown, Matthew Bower, et al.

The Lancet. Neurology|October 20, 2018

Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trialChristopher Grunseich, Ram Miller, Therese Swan, et al.

Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|November 21, 2023

Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized studyBaltazar GomezMancilla, Matthew N Meriggioli, Angela Genge, et al.

Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:

Pageof 4

You have reached the last page of results.This site can display upto 33 results.

Human Mutation|September 18, 2010

Novel LMNA mutations in patients with Emery-Dreifuss muscular dystrophy and functional characterization of four LMNA mutationsJuergen Scharner, Charlotte A Brown, Matthew Bower, et al.

The Lancet. Neurology|October 20, 2018

Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trialChristopher Grunseich, Ram Miller, Therese Swan, et al.

Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|November 21, 2023

Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized studyBaltazar GomezMancilla, Matthew N Meriggioli, Angela Genge, et al.

Pageof 4